# Trade Mark Journal No.2026/018 1 May 2026

## WO0000001908404 (35,40,42)

Office of origin: Republic of Korea

Date of International Registration:9 February 2026
Date of designation in the UK: 9 February 2026

International priority date claimed: 25 September 2025 (Republic of Korea) (4020250181079)
International priority date claimed: 25 September 2025 (Republic of Korea) (4020250181080)
International priority date claimed: 25 September 2025 (Republic of Korea) (4020250181081)

Class 35
  Advertising and commercial information services; business administration and office work; marketing services; demonstration of goods; import-export agency services; business advice for companies relating to medical services and healthcare; collection of electronic data for business purposes in the field of medicine and healthcare; on-line wholesale store services connected with the sale of pharmaceuticals; on-line retail store services connected with the sale of pharmaceuticals; wholesale store services connected with the sale of pharmaceuticals; retail store services connected with the sale of pharmaceuticals; presentation of goods on communication media, for retail purposes; providing consumer product information via the Internet; promoting the goods and services by means of operating an on-line comprehensive shopping mall; electronic data processing services relating to health care information; accountancy advice; health care cost management; statistical analysis, data evaluation and preparation of business reports relating thereto in the field of healthcare.
Class 40
  Custom manufacture of biopharmaceuticals; processing of medicinal materials; custom manufacture of pharmaceuticals; preservation of pharmaceuticals; processing of pharmaceuticals; processing of chemicals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; chemical treatment of liquids; custom manufacture of cell lines for biopharmaceutical manufacturing; custom manufacture of specific antibody-binding glycosylated drugs.
Class 42
  Science laboratory services for high-efficiency glycan analysis; culturing of cells for scientific research purposes; scientific research; biological research and analysis relating to glycosylation profiles; multiple nucleic acid analysis; protein analysis; toxicity analysis; molecular analysis; development of biotechnology; biotechnology research; biological analysis; biological research; research of biologics; biochemical analysis; biochemical research; food research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research of pharmaceuticals; pharmaceutical product evaluation; clinical research in the field of medicine; services for assessing the efficiency of pharmaceuticals; scientific research in the field of genetics and genetic engineering; genetics research; computer programming in the medical field; medical laboratories; computer software technical support service relating to management support of medical image data; medicine research; analysis and evaluation of medical product development; providing information on the testing, inspection and research of medical products; evaluating of clinical trial progress; clinical trials.

Samsung Biologics Co., Ltd.

Representative: Kilburn & Strode LLP, Lacon London, 84 Theobalds Road London WC1X 8NL UNITED KINGDOM